Treatment considerations in early breast cancer MEDSTAT_JS MEDSTAT_CSS

Treatment considerations in early breast cancer

The 2020 ASCO and SABCS meetings provided data that may have important implications in early breast cancer settings. Sara A. Hurvitz, MD, leads a virtual discussion with Kevin Kalinsky, MD, MS, Ruth O’Regan, MD, and Sara M. Tolaney, MD, MPH, in which the panel reviews recent clinical trial data and how new treatment guidance may impact patient outcomes.

Video 1: CDK4/6 inhibitors in early breast cancer

CDK4/6 inhibitors have been successful in the metastatic HR-positive/HER2-negative setting and are now being looked at in earlier stages of disease. The roundtable begins with an overview of data from the monarchE and PENELOPE-B trials and a discussion about the potential role of CDK4/6 inhibition in early HR-positive disease.

Up Next

Video 1: CDK4/6 inhibitors in early breast cancer
Video 2: RxPONDER data and the changing role of chemotherapy
Video 3: Updates in early HER2-positive breast cancer

MEDSTAT_LATEST_NEWS_WIDGET

About the Panel

Dr. Hurvitz Photo

Sara A. Hurvitz, MD

  • Associate Professor
  • Department of Hematology-Oncology
  • University of California, Los Angeles
  • Los Angeles, California
Dr. Kalinsky Photo

Kevin Kalinsky, MD, MS

  • Associate Professor, Department of Medicine
  • Director, Glenn Family Breast Center, Winship Cancer Institute
  • Emory University
  • Atlanta, Georgia
Dr. O'Regan Photo

Ruth O'Regan, MD

  • Charles A. Dewey Professor
  • Chair of Medicine, Department of Medicine
  • University of Rochester Medical Center’s School of Medicine and Dentistry
  • Rochester, New York
Dr. Tolaney Photo

Sara M. Tolaney, MD, MPH

  • Assistant Professor, Department of Medical Oncology
  • Harvard Medical School
  • Associate Director
  • Susan F. Smith Center for Women's Cancers
  • Director, Clinical Trials
  • Director, Breast Immunotherapy Clinical Research, Breast Oncology Program
  • Dana-Farber Cancer Institute
  • Boston, Massachusetts
Disclosures

Sara A. Hurvitz, MD, has disclosed the following relevant financial relationships:
Received research grant from: Ambrx; Amgen Inc.; Bayer HealthCare Pharmaceuticals; Daiichi Sankyo, Inc.; Dignitana AB; Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline; Immunomedics; MacroGenics, Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma, Inc.; Pfizer Inc; Pieris Pharmaceuticals Inc; Puma Biotechnology; Radius Health; Roche Pharma; sanofi-aventis; Seattle Genetics, Inc.

Kevin Kalinsky, MD, MS, has disclosed no relevant financial relationships.

Ruth O'Regan, MD, has disclosed no relevant financial relationships.

Sara M. Tolaney, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a consultant, advisor, and/or principal investigator of a study for: AstraZeneca; Eli Lilly and Company; Merck; Nektar; Novartis; Pfizer; Genentech/Roche; Immunomedics; Exelixis; Bristol Myers Squibb; Eisai; Nanostring; Puma; Cyclacel; Sanofi; Celldex; Odonate; Seattle Genetics; Daiichi Sankyo; Silverback Therapeutics; G1 Therapeutics; AbbVie; Athenex; OncoPep; Kyowa Kirin Pharmaceuticals; Samsung Bioepis Inc.
Institution received research funds from: AstraZeneca; Eli Lilly and Company; Merck; Nektar; Novartis; Pfizer; Genentech/Roche; Immunomedics; Exelixis; Bristol Myers Squibb; Eisai; Nanostring; Cyclacel; Sanofi; Odonate; Seattle Genetics.
Received an honorarium from: AstraZeneca; Eli Lilly and Company; Merck; Nektar; Novartis; Pfizer; Genentech/Roche; Immunomedics; Bristol Myers Squibb; Eisai; Nanostring; Puma; Sanofi; Celldex; Odonate; Seattle Genetics; Daiichi Sankyo; Silverback Therapeutics; G1 Therapeutics; AbbVie; Athenex; OncoPep; Kyowa Kirin Pharmaceuticals; Samsung Bioepis Inc.; CytomX.
Received travel reimbursement from: Nektar.
Serve(d) on the Steering Committee for: CytomX.